FOXD1 Expression Is Associated with Poor Prognosis in Non-small Cell Lung Cancer

被引：4

作者：

Nakayama, Sohei ^{[1
]}

Soejima, Kenzo ^{[1
]}

Yasuda, Hiroyuki ^{[1
]}

Yoda, Satoshi ^{[1
]}

Satomi, Ryosuke ^{[1
]}

Ikemura, Shinnosuke ^{[1
]}

Terai, Hideki ^{[1
]}

Sato, Takashi ^{[1
]}

Yamaguchi, Norihiro ^{[2
]}

Hamamoto, Junko ^{[1
]}

Arai, Daisuke ^{[1
]}

Ishioka, Kota ^{[1
]}

Ohgino, Keiko ^{[1
]}

Naoki, Katsuhiko ^{[1
,3
]}

Betsuyaku, Tomoko ^{[1
]}

机构：

[1] Keio Univ, Sch Med, Dept Med, Div Pulm Med, Tokyo 1608582, Japan

[2] Beth Israel Deaconess Med Ctr, Dept Internal Med, New York, NY USA

[3] Keio Univ Hosp, Keio Canc Ctr, Tokyo, Japan

来源：

ANTICANCER RESEARCH | 2015年 / 35卷 / 01期

关键词：

FOXD1; non-small cell lung cancer; microarray; pathway signature; PTEN; GENE-EXPRESSION; PTEN LOSS; SIGNATURES; AKT; METASTASIS; SUPPRESSOR; ERLOTINIB; PROTEINS; SURVIVAL; FOXA2;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: Clinical microarray datasets were analyzed to search for new therapeutic targets and prognostic markers of non-small cell lung cancer (NSCLC). Materials and Methods: Microarray datasets from 90 lung cancer specimens, were analyzed with focus on the FOXD1 gene. Levels of FOXDI mRNA were assessed in lung cancer cell lines and these levels were correlated with survival. Results: FOXD1-knockdown led to suppression of cell proliferation. Moreover, patients with high FOXDI expression survived for a significantly shorter time than those with low FOXDI expression. Conclusion: The expression status of FOXD1 is a novel prognostic factor and may lead to new treatment strategies for NSCLC.

引用

页码：261 / 268

页数：8

共 50 条

[21] High integrin α3 expression is associated with poor prognosis in patients with non-small cell lung cancer
Li, Qianping
Ma, Weijie
Chen, Shuai
Tian, Eddie C.
Wei, Sixi
Fan, Reggie R.
Wang, Tao
Zhou, Chihong
Li, Tianhong
TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (04) : 1361 - 1378
[22] Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer
Guo, Weigang
Zhang, Yongxing
Zhang, Yi
Shi, Yu
Xi, Junjie
Fan, Hong
Xu, Songtao
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2015, 36 (06) : 1720 - 1726
[23] Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer
Ohgino, Keiko
Soejima, Kenzo
Yasuda, Hiroyuki
Hayashi, Yuichiro
Hamamoto, Junko
Naoki, Katsuhiko
Arai, Daisuke
Ishioka, Kota
Sato, Takashi
Terai, Hideki
Ikemura, Shinnosuke
Yoda, Satoshi
Tani, Tetsuo
Kuroda, Aoi
Betsuyaku, Tomoko
LUNG CANCER, 2014, 83 (01) : 90 - 96
[24] Expression of LRIG1 is Associated With Good Prognosis for Human Non-small Cell Lung Cancer
An, Yuzhi
Zhao, Zibo
Ou, Pengju
Wang, Guangchuan
MEDICINE, 2015, 94 (47) : e2081
[25] Low LATS2 EXPRESSION IS ASSOCIATED WITH POOR PROGNOSIS IN NON-SMALL CELL LUNG CARCINOMA
Jang, Si-Hyong
Oh, Mee-Hye
Cho, Hyun Deuk
Lee, Ji-Hye
Lee, Hyun Ju
Ahn, Hyein
Kim, Han Jo
POLISH JOURNAL OF PATHOLOGY, 2019, 70 (03) : 189 - 197
[26] High expression of MYEOV reflects poor prognosis in non-small cell lung cancer
Zhang, Rui
Ma, Aiqing
GENE, 2021, 770
[27] Loss of Bad expression confers poor prognosis in non-small cell lung cancer
Yi Huang
Dan Liu
Bojiang Chen
Jing Zeng
Lei Wang
Shangfu Zhang
Xianming Mo
Weimin Li
Medical Oncology, 2012, 29 : 1648 - 1655
[28] GNPNAT1 Predicts Poor Prognosis and Cancer Development in Non-Small Cell Lung Cancer
Feng, Yong
Li, Na
Ren, Yi
CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 2419 - 2428
[29] Elevated expression of Cripto-1 correlates with poor prognosis in non-small cell lung cancer
Xu, Chun-Hua
Sheng, Zhi-Hong
Hu, Hui-Di
Hao, Ke-Ke
Wang, Qing-Bo
Yu, Li-Ke
TUMOR BIOLOGY, 2014, 35 (09) : 8673 - 8678
[30] FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients
Wang, Yu
Wen, Li
Zhao, Shu-hua
Ai, Zhen-hua
Guo, Jun-zhao
Liu, Wen-chao
LUNG CANCER, 2013, 79 (02) : 173 - 179

← 1 2 3 4 5 →